These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25152704)

  • 1. Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC).
    Bielecka ZF; Czarnecka AM; Solarek W; Kornakiewicz A; Szczylik C
    Curr Signal Transduct Ther; 2014 Dec; 8(3):218-228. PubMed ID: 25152704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.
    Bielecka ZF; Malinowska A; Brodaczewska KK; Klemba A; Kieda C; Krasowski P; Grzesiuk E; Piwowarski J; Czarnecka AM; Szczylik C
    Cell Biosci; 2017; 7():71. PubMed ID: 29270287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma.
    Wang L; Li Y; Lyu Y; Wen H; Feng C
    Cancer Cell Int; 2020; 20():482. PubMed ID: 33041663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.
    Ranieri G; Marech I; Niccoli Asabella A; Di Palo A; Porcelli M; Lavelli V; Rubini G; Ferrari C; Gadaleta CD
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
    Li Y; Shen Y; Zhu Z; Wen H; Feng C
    Cancer Med; 2020 Aug; 9(16):6020-6029. PubMed ID: 32628820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment.
    Juengel E; Schnalke P; Rutz J; Maxeiner S; Chun FK; Blaheta RA
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
    Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
    Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
    Randrup Hansen C; Grimm D; Bauer J; Wehland M; Magnusson NE
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivozanib in the treatment of renal cell carcinoma.
    Hepgur M; Sadeghi S; Dorff TB; Quinn DI
    Biologics; 2013; 7():139-48. PubMed ID: 23788831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
    Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
    Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.
    Pal SK; Signorovitch JE; Li N; Zichlin ML; Liu Z; Ghate SR; Perez JR; Vogelzang NJ
    Int J Urol; 2017 Apr; 24(4):272-278. PubMed ID: 28253548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.
    Comandone A; Vana F; Comandone T; Tucci M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.